Literature DB >> 20887270

Defining the role of food allergy in a population of adult patients with eosinophilic esophagitis.

Maria del Robledo Avila Castellano1, Stefan Cimbollek, Joaquin Quiralte.   

Abstract

The aim of this study was to establish the clinical types of food reactions and the food sensitization profile in an adult cohort of patients with (EoE). We have prospectively analyzed the food allergen sensitization profile using skin prick test (SPT) and atopy patch test (APT) to 22 plant and animal-derived foods in 19 adult patients with biopsy-proven EoE. For each patient the following data was collected: age, sex, atopic disease status, and clinical characteristics of the EoE. A total of 123 food sensitizations were detected by SPT and 45 food sensitizations by patch testing in 18 patients (94.8%). Thirty-five double- positive (SPT+, APT+) responses against the same food were detected in 15 patients (78.9%). We have also identified 11 clinical episodes clearly suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after intake of some specific foods. All cases showed positive SPT to the offending food (Type 1 food reactors). 68 clinically apparent episodes of EoE related with specific foods were detected in our patients. In 40 instances (58.8%) the foods involved in developing EoE symptoms showed a positive SPT and/or APT results (Type 2). 155 food sensitizations were identified in 18 patients (94.7%) using SPT and/or APT neither related with clinically apparent episodes of EoE nor with clinical episodes suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after food intake (Type 3). In conclusion, the patients with EoE can be allocated into 3 different groups of food reactors, with well-defined clinical and biological characteristics.

Entities:  

Mesh:

Year:  2010        PMID: 20887270     DOI: 10.2174/187152810793358804

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  8 in total

Review 1.  Unmet therapeutic needs in eosinophilic esophagitis.

Authors:  Seema S Aceves
Journal:  Dig Dis       Date:  2014-02-28       Impact factor: 2.404

2.  Longitudinal Growth Outcomes Following First-line Treatment for Pediatric Patients With Eosinophilic Esophagitis.

Authors:  Elizabeth T Jensen; Kevin Z Huang; Hannah X Chen; Lisa E Landes; Kristen A McConnell; Mary Angie Almond; Anca M Safta; Douglas T Johnston; Raquel Durban; Laura Jobe; Carrie Frost; Sarah Donnelly; Brady Antonio; Antonio Quiros; Jonathan E Markowitz; Evan S Dellon
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-01       Impact factor: 2.839

Review 3.  Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review.

Authors:  James S Pearson; Robert M Niven; Jie Meng; Sima Atarodi; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

4.  The role of allergy evaluation in children with eosinophilic esophagitis.

Authors:  Abdulrahman Al-Hussaini; Eman Al-Idressi; Mofareh Al-Zahrani
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

5.  Food allergy testing in eosinophilic esophagitis: what the gastroenterologist needs to know.

Authors:  Seema S Aceves
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-11       Impact factor: 11.382

6.  The Role of Allergy Testing in Eosinophilic Esophagitis.

Authors:  Adjoa Anyane-Yeboa; Wenfei Wang; Robert T Kavitt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-08

Review 7.  Diagnosis of Food Allergy.

Authors:  Rebecca Sharon Chinthrajah; Dana Tupa; Benjamin T Prince; Whitney Morgan Block; Jaime Sou Rosa; Anne Marie Singh; Kari Nadeau
Journal:  Pediatr Clin North Am       Date:  2015-09-07       Impact factor: 3.278

8.  Genetic variations in the TLR3 locus are associated with eosinophilic esophagitis.

Authors:  Robledo Ávila-Castellano; José-Raúl García-Lozano; Stefan Cimbollek; Alfredo J Lucendo; Juan-Manuel Bozada; Joaquín Quiralte
Journal:  United European Gastroenterol J       Date:  2017-09-13       Impact factor: 4.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.